ArticleThe Journal of experimental medicine2020
SARS-CoV-2 vaccine development, access, and equity.
Article in The Journal of experimental medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 11 citations in OpenAlex.
- Development of nucleic acid-based vaccines against dengue and other mosquito-borne flaviviruses: the past, present, and future.Frontiers in immunology · 2024Review
- Death Reporting in Breakthrough and Unvaccinated SARS-CoV-2 Infection Cases.Disaster medicine and public health preparedness · 2023Article
- Adenovirus-vectored SARS-CoV-2 vaccine expressing S1-N fusion protein.Antibody therapeutics · 2022Article
- The Vaccination Process against the COVID-19: Opportunities, Problems andHealthcare (Basel, Switzerland) · 2021Article
- Supply and delivery of vaccines for global health.Current opinion in immunology · 2021Review
- Vaccine development for emerging infectious diseases.Nature medicine · 2021Review
- Advocating for Greater Inclusion of Marginalized and Forgotten Populations in COVID19 Vaccine Rollouts.International journal of public health · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over the past 9 mo, with 34 million infections and 1 million deaths, the COVID-19 pandemic has levied a grisly toll. Some countries, through political will and social organization, have successfully reduced the number of infections and deaths, but the global scale of loss reflects the difficulty of translating these approaches in other countries. An effective SARS-CoV-2 vaccine presents a technological solution to the failure of social and political ones. Vaccines are, however, not a silver bullet, but a safe, cost-effective, and globally applicable tool that will require a substantial effort-cooperation, commitment, time, and funding-to be effective.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.